✓ Translated by DotMD AI Clinical Council Source: Breast (Edinburgh, Scotland) • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #40633461 ↗

Phase III Randomized Trial: Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?

Original Paper Title: “Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Combining molecular and clinico-pathologic factors enhances prognostic information. However, the impact of this on actual patient management requires further prospective validation.
  • Study Design & Sample: Phase III Randomized Trial published in Breast (Edinburgh, Scotland) (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Breast (Edinburgh, Scotland) (2025), this phase iii randomized trial evaluating human clinical outcomes investigated: Few studies have compared the performance of gene-expression profiling tests (e.g. Key clinical takeaway: Combining molecular and clinico-pathologic factors enhances prognostic information. However, the impact of this on actual patient management requires further prospective validation.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Breast (Edinburgh, Scotland), 2025-10-15; Phase III Randomized Trial; Rigor 82/100): Combining molecular and clinico-pathologic factors enhances prognostic information. However, the impact of this on actual patient management requires further prospective validation.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: tamoxifen-citrate → Rx: exemestane → Condition: giant-cell-tumor-of-soft-parts → Condition: metatypical-carcinoma →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 40633461: Phase III Randomized Trial: Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?

3 of 3 Free Questions Remaining